Cargando…
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508135/ https://www.ncbi.nlm.nih.gov/pubmed/37322852 http://dx.doi.org/10.1002/cac2.12456 |
| _version_ | 1785107468145131520 |
|---|---|
| author | Wang, Pingli Cao, Liming Tian, Panwen Ren, Shengxiang Miao, Liyun Zhou, Chengzhi Fan, Yun Li, Yuping Lv, Dongqing Zhao, Xin Yang, Mei Zhu, Chaonan Yu, Bing Xu, June Song, Yong Wang, Kai |
| author_facet | Wang, Pingli Cao, Liming Tian, Panwen Ren, Shengxiang Miao, Liyun Zhou, Chengzhi Fan, Yun Li, Yuping Lv, Dongqing Zhao, Xin Yang, Mei Zhu, Chaonan Yu, Bing Xu, June Song, Yong Wang, Kai |
| author_sort | Wang, Pingli |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10508135 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105081352023-09-20 A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations Wang, Pingli Cao, Liming Tian, Panwen Ren, Shengxiang Miao, Liyun Zhou, Chengzhi Fan, Yun Li, Yuping Lv, Dongqing Zhao, Xin Yang, Mei Zhu, Chaonan Yu, Bing Xu, June Song, Yong Wang, Kai Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2023-06-15 /pmc/articles/PMC10508135/ /pubmed/37322852 http://dx.doi.org/10.1002/cac2.12456 Text en © 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Wang, Pingli Cao, Liming Tian, Panwen Ren, Shengxiang Miao, Liyun Zhou, Chengzhi Fan, Yun Li, Yuping Lv, Dongqing Zhao, Xin Yang, Mei Zhu, Chaonan Yu, Bing Xu, June Song, Yong Wang, Kai A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title | A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title_full | A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title_fullStr | A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title_full_unstemmed | A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title_short | A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations |
| title_sort | phase ii study on mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon egfr mutations |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508135/ https://www.ncbi.nlm.nih.gov/pubmed/37322852 http://dx.doi.org/10.1002/cac2.12456 |
| work_keys_str_mv | AT wangpingli aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT caoliming aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT tianpanwen aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT renshengxiang aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT miaoliyun aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhouchengzhi aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT fanyun aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT liyuping aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT lvdongqing aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhaoxin aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT yangmei aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhuchaonan aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT yubing aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT xujune aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT songyong aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT wangkai aphaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT wangpingli phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT caoliming phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT tianpanwen phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT renshengxiang phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT miaoliyun phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhouchengzhi phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT fanyun phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT liyuping phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT lvdongqing phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhaoxin phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT yangmei phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT zhuchaonan phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT yubing phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT xujune phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT songyong phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations AT wangkai phaseiistudyonmefatinibasfirstlinetreatmentofpatientswithadvancednonsmallcelllungcancerharboringuncommonegfrmutations |